Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Ascending Doses of ASP015K in Healthy Subjects
NCT02141425Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of peficitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Safety as assessed by adverse events, clinical laboratory tests, electrocardiogram (ECG) measurements, physical examination abnormalities and vital signs. Started Mar 2014; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02141425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141425.